Nebraska Medicine Hematology/Oncology

www.nebraskamed.com

 

Rivaroxaban Inferior to Warfarin in Prevention of Recurrent Thrombosis in Antiphospholipid Ab Syndrome & Andexanet and Idarucizumab Safe and Effective at Reversing Anticoagulant Effects of DOACs

202 views
March 9, 2020
0 Comments
Login to view comments. Click here to Login
Hematology Highlights: A Post ASH Review